|
|
AAV Vector Mediated Gene Therapy in Pompe Model Mice |
Zhi-jie WU1,2,Wen-hao MA2,Zhe-yue DONG2,Xiao-bing WU2,**(),Yi-shu YANG1,**(),Wang SHENG1 |
1. Beijing University of Technology, Beijing 100124,China 2. Beijing GeneCradle Pharmaceutical Co Ltd, Beijing 100176,China |
|
|
Abstract Objective: Pompe disease is a lysosomal glycogen storage disease caused by acid α-glucosidase (GAA) deficiency, which is characterized by glycogen accumulation in the heart, skeletal muscle, and central nervous system (CNS). AAV vector-mediated gene therapy is expected to be a breakthrough in the treatment of Pompe disease. In this study, AAV9 vector was used to mediate GAA gene transfer in Pompe disease model mice, and the changes of GAA protease activity, glycogen accumulation in tissues and pathological changes in mice after transgenic intervention were evaluated. Methods: Codon optimized GAA gene (coGAA) was carried by AAV9 vector, and the AAV vector was packaged by baculovirus production process. Adult Pompe model mice were given a single intravenous injection at the dose of 1.1×1013, 3.0×1013, 1.2×1014 vg/kg, and aged Pompe model mice were given a single intravenous injection at the dose of 3.0×1013 vg/kg. After reaching the end point of the experiment, the mice were euthanized, GAA protease activity was determined by fluorescence spectrophotometry, glycogen accumulation was observed by PAS staining, and pathological changes were detected by HE staining. Results: Five weeks after administration, GAA protein was widely expressed in all tissues of adult model mice, with higher expression levels in heart and liver, and lower expression levels in brain and spinal cord. After rAAV9-coGAA treatment, glycogen content in myocardium, skeletal muscle and brain decreased, and vacuolar degeneration in myocardium and skeletal muscle decreased significantly. After treatment, the tissue enzyme activity of the aged animals was significantly increased compared with that of the model mice. The vacuolar degeneration and inflammatory cell infiltration of the myocardium were decreased, but the pathological improvement of skeletal muscle was limited. Conclusion: A single intravenous injection of rAAV9-coGAA can enhance GAA enzyme activity, reduce glycogen accumulation and improve pathology in Pompe model mice. The therapeutic effect was dose-dependent, and the injection also had certain therapeutic effect on aged animals. This study laid a theoretical foundation for the clinical application of AAV9 mediated gene therapy via intravenous route in Pompe disease.
|
Received: 24 February 2022
Published: 03 August 2022
|
|
Corresponding Authors:
Xiao-bing WU,Yi-shu YANG
E-mail: wuxiaobing@bj;yishu-y@bjut.edu.cn
|
|
|
[1] |
Kohler L, Puertollano R, Raben N. Pompe disease: from basic science to therapy. Neurotherapeutics, 2018, 15(4): 928-942.
doi: 10.1007/s13311-018-0655-y
pmid: 30117059
|
|
|
[2] |
Taverna S, Cammarata G, Colomba P, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging, 2020, 12(15): 15856-15874.
doi: 10.18632/aging.103794
|
|
|
[3] |
中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会医学遗传学分会, 中华医学会儿科学分会罕见病学组, 等. 儿童糖原累积病Ⅱ型诊断及治疗中国专家共识. 中华儿科杂志, 2021, 59(6): 439-445.
|
|
|
[3] |
The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association; the Society of Medical Genetics, Chinese Medical Association; the Subspecialty Group of Rare Diseases, the Society of Pediatrics, Chinese Medical Association, et al. Chinese experts consensus on diagnosis and treatment of glycogen storage disease type Ⅱ in children. Chinese Journal of Pediatrics, 2021, 59(6): 439-445.
|
|
|
[4] |
Colella P, Mingozzi F. Gene therapy for pompe disease: the time is now. Human Gene Therapy, 2019, 30(10): 1245-1262.
doi: 10.1089/hum.2019.109
|
|
|
[5] |
Kishnani P S, Hwu W L, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. The Journal of Pediatrics, 2006, 148(5): 671-676.e2.
doi: 10.1016/j.jpeds.2005.11.033
|
|
|
[6] |
van Capelle C I, van der Meijden J C, van den Hout J M P, et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet Journal of Rare Diseases, 2016, 11(1): 65.
doi: 10.1186/s13023-016-0442-y
pmid: 27189384
|
|
|
[7] |
Preisler N, Lukacs Z, Vinge L, et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Molecular Genetics and Metabolism, 2013, 110(3): 287-289.
doi: 10.1016/j.ymgme.2013.08.005
pmid: 24011652
|
|
|
[8] |
Falk D J, Soustek M S, Todd A G, et al. Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Molecular Therapy - Methods & Clinical Development, 2015, 2: 15007.
|
|
|
[9] |
Costa-Verdera H, Collaud F, Riling C R, et al. Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human Primates. Nature Communications, 2021, 12: 6393.
doi: 10.1038/s41467-021-26744-4
pmid: 34737297
|
|
|
[10] |
Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Molecular Therapy, 2008, 16(6): 1073-1080.
doi: 10.1038/mt.2008.76
pmid: 18414476
|
|
|
[11] |
Yu Z, Zhou S, Luo N, et al. Three-phase partitioning combined with density gradient ultracentrifugation as an economic and universal process for large scale purification of AAV vectors. Molecular Therapy - Methods & Clinical Development, 2019, 17:34-48.
|
|
|
[12] |
Werling N J, Satkunanathan S, Thorpe R, et al. Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products. Human Gene Therapy Methods, 2015, 26(3): 82-92.
doi: 10.1089/hgtb.2015.013
|
|
|
[13] |
Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. The Journal of Biological Chemistry, 1998, 273(30): 19086-19092.
doi: 10.1074/jbc.273.30.19086
|
|
|
[14] |
马文豪, 章嫣, 董哲岳, 等. 携带CAR启动子的重组AAV9病毒在小鼠体内表达分布特性研究. 病毒学报, 2019, 35(3): 423-430.
|
|
|
[14] |
Ma W H, Zhang Y, Dong Z Y, et al. Biodistribution of adeno-associated virus 9-mediated gene expression with a CAR promoter in mice. Chinese Journal of Virology, 2019, 35(3): 423-430.
|
|
|
[15] |
Kishnani P S, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease. The Journal of Pediatrics, 2006, 149(1): 89-97.
doi: 10.1016/j.jpeds.2006.02.035
|
|
|
[16] |
Chan J, Desai A K, Kazi Z B, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Molecular Genetics and Metabolism, 2017, 120(3): 163-172.
doi: 10.1016/j.ymgme.2016.12.004
|
|
|
[17] |
Samulski R J, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annual Review of Virology, 2014, 1(1): 427-451.
doi: 10.1146/annurev-virology-031413-085355
pmid: 26958729
|
|
|
[18] |
Verdera H C, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Molecular Therapy, 2020, 28(3): 723-746.
doi: S1525-0016(20)30003-4
pmid: 31972133
|
|
|
[19] |
Weber T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Frontiers in Immunology, 2021, 12: 658399.
doi: 10.3389/fimmu.2021.658399
|
|
|
[20] |
Salabarria S M, Nair J, Clement N, et al. Advancements in AAV-mediated gene therapy for pompe disease. Journal of Neuromuscular Diseases, 2020, 7(1): 15-31.
doi: 10.3233/JND-190426
pmid: 31796685
|
|
|
[21] |
ElMallah M K, Falk D J, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Molecular Therapy, 2014, 22(4): 702-712.
doi: 10.1038/mt.2013.282
|
|
|
[22] |
Falk D J, Mah C S, Soustek M S, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Molecular Therapy, 2013, 21(9): 1661-1667.
doi: 10.1038/mt.2013.96
|
|
|
[23] |
Amalfitano A, Mcvie-Wylie A J, Hu H, et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96(16): 8861-8866.
|
|
|
[24] |
Han S O, Ronzitti G, Arnson B, et al. Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Molecular Therapy - Methods & Clinical Development, 2017, 4: 126-136.
|
|
|
[25] |
Ronzitti G, Collaud F, Laforet P, et al. Progress and challenges of gene therapy for Pompe disease. Annals of Translational Medicine, 2019, 7(13): 287.
doi: 10.21037/atm.2019.04.67
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|